View on Pubmed.gov 39831520 | View on doi.org 10.1080/2150559...
Immunogenicity and vaccine efficacy of Actinobacillus pleuropneumoniae-derived extracellular vesicles as a novel vaccine candidate.
- Biological Resource Center, Korea Research Institute of Bioscience and Biotechnology, Jeongeup, Korea.
- Functional Biomaterial Research Center, Korea Research Institute of Bioscience and Biotechnology, Jeongeup, Republic of Korea.
- Department of Food and Nutrition, Chungnam National University, Daejeon, Republic of Korea.
- Functional Biomaterial Research Center, Korea Research Institute of Bioscience and Biotechnology, Jeongeup, Republic of Korea. Department of Medical Science, College of Medicine, Chungnam National University, Daejeon, Republic of Korea.
- Department of Microbiology and Immunology, College of Medicine, Seoul National University, Seoul, Republic of Korea. Institute for Data Innovation in Science, Seoul National University, Seoul, Republic of Korea.
- Vaccine Lab, WOOGENE B&G Co. LTD, Seoul, Republic of Korea.
Abstract
Actinobacillus pleuropneumoniae (APP) is a significant pathogen in the swine industry, leading to substantial economic losses and highlighting the need for effective vaccines. This study evaluates the potential of APP-derived extracellular vesicles (APP-EVs) as a vaccine candidate compared to the commercial Coglapix vaccine. APP-EVs, isolated using tangential flow filtration (TFF) and cushioned ultracentrifugation, exhibited an average size of 105 nm and a zeta potential of -17.4 mV. These EVs demonstrated stability under external stressors, such as pH changes and enzymatic exposure and were found to contain 86 major metabolites. Additionally, APP-EVs induced dendritic cell (DC) maturation in a Toll-like receptor 4 (TLR4)-dependent manner without cytotoxicity. APP-EVs predominantly elicited Th1-mediated IgG responses in immunized mice without significant liver and kidney toxicity. Contrarily, unlike Coglapix, which induced stronger Th2-mediated responses and notable toxicity. In addition, APP-EVs triggered APP-specific Th1, Th17, and cytotoxic T lymphocyte (CTL) responses and promoted the activation of multifunctional T-cells. Notably, APP-EV immunization enhanced macrophage phagocytosis and improved survival rates in mice challenged with APP infection compared to those treated with Coglapix. These findings suggest that APP-EVs are promising vaccine candidates, capable of inducing potent APP-specific T-cell responses, particularly Th1, Th17, CTL, and multifunctional T-cells, thereby enhancing the protective immune response against APP infection.
References
Antibiotics (Basel). 2023 Aug 08;12(8):
Pathogens. 2024 May 15;13(5):
J Transl Med. 2021 May 11;19(1):202
Nat Rev Immunol. 2002 Jun;2(6):401-9
Cited by
Journal Article Review
Nanomaterial Adjuvants for Veterinary Vaccines: Mechanisms and Applications.
Electronic publication date July 10, 2025
Li He [...] Yuli Li et al.
Safe and effective veterinary vaccines prevent infectious diseases and reduce morbidity. In this field, nanovaccines based on nanomaterials are emerging,...
Conflict of interest statement
MeSH
- •
- •
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
- •
Substances
- •
- •